Tonix Pharmaceuticals Holding Corp
$ 11.35
6.57%
12 Jun - close price
- Market Cap 180,928,000 USD
- Current Price $ 11.35
- High / Low $ 11.40 / 10.41
- Stock P/E N/A
- Book Value 19.17
- EPS -14.66
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.42 %
- ROE -0.72 %
- 52 Week High 69.97
- 52 Week Low 10.03
About
Tonix Pharmaceuticals Holding Corp. The company is headquartered in Chatham, New Jersey.
Analyst Target Price
$46.25
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-03-12 | 2025-11-10 | 2025-08-11 | 2025-05-12 | 2025-03-18 | 2024-11-12 | 2024-08-16 | 2024-04-01 | 2024-03-25 | 2023-11-09 | 2023-08-10 |
| Reported EPS | -2.93 | -3.9818 | -3.59 | -3.86 | -2.642 | -9.767 | -0.2288 | -19.28 | -0.18 | -0.86 | -1.83 | -2.68 |
| Estimated EPS | -2.55 | -3.19 | -3.59 | -6.83 | -3.09 | -3.91 | -2.93 | -3.27 | -0.39 | -1.64 | -1.49 | -2.75 |
| Surprise | -0.38 | -0.7918 | 0 | 2.97 | 0.448 | -5.857 | 2.7012 | -16.01 | 0.21 | 0.78 | -0.34 | 0.07 |
| Surprise Percentage | -14.902% | -24.8213% | 0% | 43.4846% | 14.4984% | -149.7954% | 92.1911% | -489.6024% | 53.8462% | 47.561% | -22.8188% | 2.5455% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TNXP
2026-06-12 13:39:58
This article provides various trading ideas for Tonix Pharmaceuticals Holding Corp. (TRADEGATE:TPM0), with traders offering analyses on potential price movements, channel trends, and upcoming catalysts like FDA approval. Several contributors suggest long positions based on technical analysis and anticipated positive news.
2026-06-11 22:39:58
Tonix Pharmaceuticals Holding Corp. announced its participation in BTIG’s Infectious Disease Day 2026, where President and CEO Seth Lederman, M.D., will hold virtual 1x1 meetings on June 16, 2026. The company, a commercial-stage biotechnology firm, focuses on CNS and immunology treatments, including its fibromyalgia treatment TONMYA® and a pipeline of drugs for Lyme disease, kidney transplant rejection, and Prader-Willi syndrome.
2026-06-11 10:39:37
Tonix Pharmaceuticals Holding Corp. announced its management team, led by President and CEO Seth Lederman, M.D., will participate in 1x1 meetings at BTIG’s Infectious Disease Day 2026 on June 16, 2026. The company is a commercial-stage biotechnology firm specializing in CNS and immunology treatments, including its fibromyalgia drug TONMYA®, and has a pipeline of immunology and rare disease programs. This virtual event provides an opportunity for Tonix to engage with the investment community.
2026-06-10 11:09:26
Tonix Pharmaceuticals Holding Corp. CEO Seth Lederman has acquired 5,000 shares of common stock in an open-market transaction on June 9, 2026. The shares were purchased at a weighted average price of $11.79 per share, totaling approximately $59,000. Following this acquisition, Lederman now directly holds 9,005 shares, with additional indirect holdings through an IRA account and Lederman & Co.
2026-06-09 22:40:48
Richard Newcomb Stillwell, a director at Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), recently purchased 5,000 shares of the company's common stock for $58,250 at a weighted average price of $11.65 per share. This purchase occurred while the stock was near its 52-week low, and InvestingPro analysis suggests the company is undervalued. Meanwhile, Tonix Pharmaceuticals has expanded commercial coverage for its fibromyalgia treatment, TONMYA, and advanced research initiatives for other drug candidates.
2026-06-09 21:40:48
This article details an insider trading activity for Tonix Pharmaceuticals Holding Corp. (TNXP) filed on Form 4. Director Richard Newcomb Stillwell purchased 5,000 shares of common stock for $58,250, at an average price of $11.65 per share. This transaction increases his direct holdings to 5,000 shares.
